Wall Street is positive on Lyell Immunopharma Inc (LYEL). On average, analysts give Lyell Immunopharma Inc a Buy rating. The average price target is $6.8, which means analysts expect the stock to increase by 309.64% over the next twelve months.
That average ranking earns Lyell Immunopharma Inc an Analyst Rating of 30, which is better than 30% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating LYEL a Buy today. Find out what this means to you and get the rest of the rankings on LYEL!
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With Lyell Immunopharma Inc Stock Today?
Lyell Immunopharma Inc (LYEL) stock is lower by -24.43% while the S&P 500 is up 1.14% as of 1:18 PM on Friday, Nov 10. LYEL is down -$0.54 from the previous closing price of $2.19 on volume of 631,823 shares. Over the past year the S&P 500 is higher by 11.13% while LYEL is down -66.53%. LYEL lost -$0.76 per share the over the last 12 months.
Click Here to get the full Stock Report for Lyell Immunopharma Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
